secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001104659-24-029378
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva Q4 net income $61.5M, royalty revenue $69.6M; product sales up 35% YoY
-------------------------------------------------------------------------------

- Q4 net income $61.5M ($0.97 EPS) vs $68.3M loss in Q4 2022; full-year net income $179.7M.
- Q4 GSK royalty revenue $69.6M; net product sales $19.7M (+35% YoY) driven by GIAPREZA ($13.1M) and XERAVA ($5.2M).
- Repurchased 1.1M shares for $15.4M in Q4; full-year repurchases $76.5M; $15M authorization remaining.
- XACDURO approved for HABP/VABP; zoliflodacin met Phase 3 primary endpoint; NDA filing within 12 months.
- Cash and receivables >$275M; strategic assets valued at $561M; invested $5M in Gate Neurosciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465924029378/0001104659-24-029378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465924029378/tm247467d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-029378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer